FDA Issues MDO on 65 "MNGO Disposable Stick" Vapes of Shenzhen YIBAI Technology

Regulations by 2FIRSTS
Apr.16.2024
FDA Issues MDO on 65 "MNGO Disposable Stick" Vapes of Shenzhen YIBAI Technology
FDA issues Marketing Denial Order to China's Yi Bai Technology, banning sale of 65 "MNGO Disposable Stick" e-cigarettes in US.

According to an announcement released by the United States FDA on April 15, the FDA has issued a Marketing Denial Order (MDO) to Shenzhen Yibai Technology Co., Ltd., prohibiting the sale of 65 disposable e-cigarettes named "MNGO Disposable Stick" in the United States. Failure to comply could result in legal action by the FDA against the company.

 

FDA Issues MDO on 65
Announcement | Image source: US FDA

 

The FDA has announced a ban on flavored disposable e-cigarettes, including tobacco, mint, pink lemonade, strawberry mango, watermelon ice, and ice banana flavors, with nicotine concentrations ranging from 2% to 6% for each flavor. According to the 2023 National Youth Tobacco Survey (NYTS), disposable e-cigarettes are the most commonly used device among e-cigarette users, with nearly 90% of users reporting that they use fruit-flavored e-cigarettes.

 

Dr. Brian King, Director of the FDA's Center for Tobacco Products, revealed that data submitted by Yibai Technology in their application indicated that products marketed as "Clear" flavor, claiming to be flavorless or odorless, actually contain flavoring agents or present a minty taste. Based on all evidence, the FDA has determined that these products have distinct flavors.

 

After a multidisciplinary scientific review, the FDA determined that the application materials lacked sufficient evidence to demonstrate that the marketing of the product meets the public health protection standards required by the 2009 Family Smoking Prevention and Tobacco Control Act - especially in terms of product stability, manufacturing processes, design features to prevent product tampering or misuse, and other necessary data. Therefore, the application was not sufficient to prove that flavored e-cigarettes offer additional benefits to adult smokers compared to tobacco-flavored e-cigarettes, such as aiding in quitting smoking completely or significantly reducing cigarette use, thus offsetting the risks they pose to youth.

 

The FDA has announced that it has received 26 million applications for related products, with the majority being e-cigarettes, and has already made decisions on 99% of the applications. Since December 2023, the FDA has issued market denial orders for over 20,000 flavored e-cigarette products, including Shenzhen Yibo Technology's MNGO disposable e-cigarette product.

 

As of now, the FDA has authorized the legal sale of 23 e-cigarette devices and tobacco-flavored e-cigarette products. Information on tobacco products allowed for sale by law can be found in the new tobacco product database established by the FDA.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
2Firsts Data|China’s Vape-Related Exports Rose 3.3% in August 2026 as UK Shipments Jumped 51.4% and U.S. Exports Fell 12.4%
China exported $979 million of vape-related products in August 2026, up 3.3% from a year earlier but down 6.4% from July. The UK replaced the U.S. as the main source of growth: UK-bound shipments jumped 51.4% to a 2026 high of $177 million, while exports to the U.S. fell 12.4% to $339 million. Shipments to markets outside the U.S. increased 14.2%, broadening growth beyond the market that had driven July’s rebound.
News
Sep.23 by 2Firsts Perspectives
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03